Regeneron Pharmaceuticals’ (REGN) Neutral Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note released on Monday morning, Benzinga reports. The firm currently has a $925.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on REGN. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an overweight rating in a research note on Tuesday, January 23rd. Truist Financial restated a buy rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a research note on Wednesday, March 13th. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an outperform rating in a research note on Monday, February 5th. Finally, StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a report on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $970.57.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ:REGN opened at $901.19 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $98.91 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 2.62 and a beta of 0.11. The firm’s 50-day moving average is $955.19 and its two-hundred day moving average is $890.52. Regeneron Pharmaceuticals has a 1 year low of $684.80 and a 1 year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the firm earned $10.96 earnings per share. The business’s quarterly revenue was up .6% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals will post 38.18 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold a total of 13,729 shares of company stock worth $13,124,641 in the last three months. Insiders own 8.83% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Sunbelt Securities Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. West Paces Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the last quarter. O Dell Group LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $27,000. Finally, Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.